S-BLR Versus C-BLR for CI-IXT in Children
Launched by CHEN ZHAO · Aug 19, 2019
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
Using conventional surgical procedures, higher postoperative near undercorrection and/or distant overcorrection rates were observed in CI-IXT. To achieve better outcome, S-BLR was introduced. Previous studies showed its efficacy in reducing near exodeviation, distant exodeviation, and NDD. So far, only limited studies have directly evaluated the surgical outcomes between S-BLR and C-BLR. The pilot study done by Snir et al included 12 patients with S-BLR and 6 patients with C-BLR and the success rates of S-BLR vs C-BLR were 92% vs 0 at one-year follow-up. The retrospective study done by Song...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Exodeviation at least 15 at distance (6 meters);
- • Exodeviation at most 50 at near (1/3 meter);
- • Greater exodeviation at near than at distance by 10 or more;
- • Control score of exodeviation greater than 3;
- • Best-corrected visual acuity of 20/40 or better in the worse eye, and interocular difference of less than 2 lines;
- • Myopia5.00D, hyperopia3.0D and anisometropia≤2.5D based on cycloplegic refraction
- • Optical correction needed for at least 2 weeks before evaluation of exodeviation: myopia0.5D or astigmatism1.5D in either eye, or anisometropia1.0D;
- • Written informed consent given by participants and their parents or legal guardians.
- Exclusion Criteria:
- • Prior strabismus surgery or botulinum toxin injection;
- • Coexisting vertical deviation greater than 5, oblique muscle dysfunction, torsional deviation, dissociated vertical deviation, A-V pattern, or other conditions requiring horizontal rectus transposition, oblique surgery or vertical rectus surgery;
- • Paralytic or restrictive strabismus;
- • Lateral incomitance (greater exodeviation in right or left gaze position than in primary position by 5 or more with appropriate optical correction);
- • Ocular disease other than strabismus or refractive error;
- • Previous intraocular or refractive surgery;
- • Craniofacial malformations affecting the orbit;
- • Significant neurological disorders;
- • Birth date34 weeks or birth weight1500 gram.
- • Abbreviations: CI-IXT, convergence insufficiency intermittent exotropia; D, diopter.
About Chen Zhao
Chen Zhao is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and treatments, Chen Zhao collaborates with leading researchers and healthcare institutions to design and execute rigorous clinical studies. The organization prioritizes ethical standards, patient safety, and regulatory compliance, ensuring that all trials are conducted with integrity and transparency. Through its strategic partnerships and cutting-edge methodologies, Chen Zhao aims to contribute valuable insights to the medical community and facilitate the development of effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Trial Officials
Chen Zhao, Doctor
Study Chair
Eye & ENT Hospital of Fudan University
Xiaoli Kang, Doctor
Principal Investigator
Xinhua Hospital, Shanghai Jiao Tong University
Yueping Li, Doctor
Principal Investigator
Tianjin Eye Hospital
Lianhong Zhou, Doctor
Principal Investigator
Renmin Hospital of Wuhan University
Jing Yao, Doctor
Study Director
Eye & ENT Hospital of Fudan University
Chenhao Yang, Doctor
Principal Investigator
Children's Hospital of Fudan University
Jiangtao Xu, Doctor
Principal Investigator
AIER Eye Hospital (Kunming)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials